Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
Alessio Aghemo, Massimo Colombo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonio Russo(Health Protection Agency), Matteo Banderali(University of Milan), Sara Monico(University of Milan), F Ottaviani(University of Milan), Maria Grazia Rumi(University of Milan), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Mauro Viganò(Ospedale San Giuseppe)
Cited by 7
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
The natural history of compensated cirrhosis due to hepatitis C virus
|Hepatology|2006|631
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539